Barbara Mroczkowski
Pfizer (United States)(US)
Publications by Year
Research Areas
Liver physiology and pathology, Peptidase Inhibition and Analysis, Cancer Research and Treatments, Glycosylation and Glycoproteins Research, Endoplasmic Reticulum Stress and Disease
Most-Cited Works
- → Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)(2011)909 cited
- → An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms(2007)749 cited
- → Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma(2007)643 cited
- → 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition(2016)355 cited
- → Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis(1999)201 cited
- → A calcium-dependent 35-kilodalton substrate for epidermal growth factor receptor/kinase isolated from normal tissue.(1986)200 cited
- → Recombinant Human Epidermal Growth Factor Precursor Is a Glycosylated Membrane Protein with Biological Activity(1989)110 cited
- → Phase 0 Clinical Trials: Conceptions and Misconceptions(2008)107 cited
- → Structure-based design of novel human Pin1 inhibitors (I)(2009)106 cited
- → Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), a Key Enzyme in Angiogenesis(1998)74 cited